Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead

Neumora Therapeutics, Inc. ((NMRA)) has held its Q4 earnings call. Read on for the main highlights of the call.

Neumora Therapeutics’ latest earnings call struck a cautiously optimistic tone, highlighting strong scientific progress and multiple upcoming catalysts while acknowledging setbacks in toxicology and the limits of its cash runway. Management’s confidence in the differentiated neuroscience pipeline contrasted with the clear execution and regulatory risks tied to pivotal readouts and NMRA-215 delays.

Strong Clinical Momentum and a Catalyst-Rich 12-Month Window

Neumora outlined a busy year ahead, with key readouts slated across its late- and mid-stage pipeline, positioning the company for several value-defining events. Topline Phase III KOASTAL-2 and KOASTAL-3 data, NMRA-511 MAD extension results, NMRA-898 MAD data, and eventual NMRA-215 clinical entry are expected to drive investor focus.

NMRA-511: Encouraging Phase Ib Signal in Agitation

In a prespecified Phase Ib subgroup of 53 patients with baseline NPI-AA scores of at least 4, NMRA-511 showed a Cohen’s d effect size of 0.32–0.34 on the CMAI, on par with an approved comparator. Safety looked clean, with no somnolence or sedation reported, and the company plans a MAD extension readout in H2 2026 followed by a Phase II launch in Q1 2027.

Navacaprant: Phase III KOASTAL-2 and -3 Fully Enrolled

Navacaprant’s KOASTAL-2 and KOASTAL-3 Phase III trials are now fully enrolled with more than 400 patients each, setting up a joint topline readout in Q2 2026. After lessons from KOASTAL-1, Neumora tightened monitoring, screening tools, and site selection, driving a roughly 10% higher screen-fail rate intended to enhance dataset quality.

M4 PAM Program: NMRA-898 Emerges as Lead Asset

Within its M4 PAM franchise for schizophrenia, Neumora selected NMRA-898 as lead based on favorable Phase I pharmacokinetics and pharmacodynamics. The compound’s long human half-life of about 80–100 hours supports once-daily dosing, with dose-proportional exposure, meaningful predicted free brain levels, and on-target heart rate changes; MAD data are expected in H2 2026.

NMRA-215: Compelling Obesity Data but Toxicology Overhang

NMRA-215, a CNS NLRP3 inhibitor, delivered class-leading results in a 12-week DIO mouse model, showing dose-dependent weight loss as monotherapy and additive benefit when combined with semaglutide. Switching regimens preserved semaglutide-like weight loss when animals moved to NMRA-215, supporting its potential in obesity, yet these gains are overshadowed by toxicology issues.

Rat Toxicology Findings Trigger Delay and Rework

A 13-week rat toxicology study for NMRA-215 revealed unexpected adverse findings in a small subset of animals that were not dose-dependent and not clearly on-target, raising questions about interpretation. Compounding the concern, Neumora identified study conduct issues, prompting a for-cause audit and a repeat 13-week study at a new CRO, pushing clinical entry to Q1 2027.

Study Conduct Issues Add Regulatory and Timeline Risk

The need to redo the rat study introduces additional cost, time, and regulatory uncertainty to what had looked like a high-potential metabolic program. While external consultants support the decision to repeat toxicology, investors must now factor in the possibility of further delays or design changes depending on the new data package.

Financial Position: Adequate but Finite Runway

Neumora ended 2025 with $182.5 million in cash, cash equivalents, and marketable securities, which management believes will fund operations into Q3 2027. That runway, though reasonable, must stretch across Phase III readouts, Phase II initiations, and multiple MAD programs, with some offset from reduced near-term spend on NMRA-215.

Net Loss Flat Year-over-Year Amid Heavy R&D Spend

The company reported that its 2025 net loss was comparable to 2024, underscoring that Neumora remains firmly in investment mode as it advances an expensive clinical portfolio. With no near-term path to profitability, future financing needs will depend heavily on the success of upcoming trials and any partnering or capital markets activity.

Binary Readouts and Regulatory Pathway Heighten Execution Risk

Management framed upcoming readouts in navacaprant, NMRA-511, and NMRA-898 as potential value inflection points, but these are inherently binary, and setbacks could pressure the stock and financing options. For navacaprant, the regulatory approach may lean on a single positive pivotal study plus supportive evidence, increasing the downside if pivotal outcomes are mixed.

Guidance: Multiple Readouts and Key Milestones Through 2027

Looking ahead, Neumora guided to a catalyst-rich 12–18 months with navacaprant’s KOASTAL-2 and -3 topline data in Q2 2026, NMRA-511 MAD extension data in H2 2026 and Phase II start in Q1 2027, and NMRA-898 MAD data in H2 2026. NMRA-215 is now slated for first-in-human dosing in Q1 2027 after completion of a repeat 13-week rat tox study, all supported by a cash runway projected into Q3 2027.

Neumora’s call painted a picture of a company with meaningful late-stage shots on goal in neuroscience, underpinned by differentiated mechanisms and encouraging early clinical data. Yet the NMRA-215 toxicology setback, finite cash runway, flat net loss, and reliance on binary Phase III outcomes leave investors balancing a rich catalyst calendar against tangible execution and funding risks.